Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial cancer

Share :
Published: 27 Feb 2015
Views: 2871
Rating:
Save
Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA

Dr Siefker-Radtke talks to ecancertv at ASCO GU 2015 about the results of a phase II clinical trial of DDMVAC plus bevacizumab and the merits of using basal subtyping to individualise treatment approaches.